Melanoma makes up only about 1% of skin cancers, yet it causes most skin cancer deaths. The American Cancer Society estimates that about 112,000 new invasive melanomas will be diagnosed in the U.S. this year, and that 8,510 people will die from the disease. Caught early, it is highly treatable. Once it spreads to distant organs, five-year relative survival drops to about 34%.Â
The biggest change in melanoma care over the past 15 years came from checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab. Tumors use certain proteins as brakes to hide from the immune system’s T cells, and these drugs release those brakes. The results in melanoma were striking. Even so, about half of patients do not respond.Â
That gap is why so much research now goes into active immunotherapies, often called therapeutic cancer vaccines. Instead of preventing disease, these treatments teach the immune system to recognize specific markers on tumor cells. The appeal lies in pairing the two approaches. The vaccine builds an army of cancer-fighting T cells, and the checkpoint drug keeps those cells from being switched off. The field has a long history of disappointment, though. Researchers writing in Nature noted that earlier vaccine trials had failed in late-stage patients whose tumors resisted treatment. Newer DNA and RNA designs have revived interest.Â
Regulators have also created tools to move promising therapies faster. One is the Regenerative Medicine Advanced Therapy (RMAT) designation, established under the 21st Century Cures Act. To qualify, a product must target a serious condition and show early clinical evidence that it could meet an unmet need. Benefits include intensive FDA guidance, involvement of senior agency managers, and possible rolling or priority review. It is not an approval. The product still has to prove itself in larger trials.Â
That is the backdrop for today’s update from Scancell Holdings plc (AIM: SCLP), an immunotherapy developer based in Oxford, UK, and Burlington, Massachusetts. The FDA has granted RMAT designation to its lead melanoma candidate, iSCIB1+, which the World Health Organization has now named inzitagene plasmivec. The product already held Fast Track status, granted in April.Â
The designation arrived with fresh numbers from SCOPE, a Phase 2 study in which patients with advanced melanoma received the company’s DNA immunotherapies on top of standard checkpoint drugs. In a data cut analyzed last week, overall survival at 24 months was 82% across 80 patients in the SCIB1 and iSCIB1+ groups, and 87% for those given iSCIB1+. Progression-free survival, meaning patients whose cancer had not worsened, was 71% at two years for iSCIB1+. Across both groups, 28% of patients had a complete response, with no detectable disease.Â
Those figures need context. The company compares its 71% result with the 41.5% two-year progression-free survival reported for ipilimumab plus nivolumab in CheckMate 067, a separate, earlier trial. That is a historical benchmark, not a control group within SCOPE, which was a single-arm study. Patient populations differ between trials, so a randomized Phase 3 is the real test.Â
Scancell says that global Phase 3 trial remains on track to enroll its first patient in December, following FDA clearance and authorization from UK regulators. Earlier company filings put planned enrollment at approximately 550 patients.Â
Paying for the trial depends on a pending merger with Neuphoria Therapeutics Inc. (NASDAQ: NEUP). Under the all-share deal announced on July 23rd, Scancell would acquire Neuphoria and list on Nasdaq under the symbol SCLT while keeping its AIM listing. Existing Scancell shareholders would own about 85.5% of the combined company. The plan includes up to $89 million in equity and debt financing, and the deal cannot close without at least $75 million. Neuphoria stockholders still have to approve it, and the company expects the listing to be completed in late 2026 or early 2027.Â
Scancell now has a regulator willing to work closely with it and survival numbers that compare well against historical benchmarks. Two questions remain. The first is about money, because Phase 3 funding depends on the Neuphoria deal closing. The second is about the science, because the Phase 2 results still have to hold up in a randomized trial. More mature SCOPE data, due in the first half of 2027, will give an early read, but Phase 3 will deliver the real answer.
